Published in Br J Clin Pharmacol on December 01, 1979
Cimetidine and ranitidine: comparison of effects on hepatic drug metabolism. Br Med J (1980) 2.09
Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci U S A (1985) 1.62
Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest (1989) 1.59
Omeprazole: effects on oxidative drug metabolism. Br J Clin Pharmacol (1984) 0.92
Estimation of biliary excretion of ureidopenicillins in healthy volunteers using marker dilution technique. Br J Clin Pharmacol (1982) 0.83
Interpretation of CO2 exhalation rate data from demethylation of aminopyrine and its metabolite monomethylaminoantipyrine. Br J Clin Pharmacol (1982) 0.75
Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. Ireland, 6-8 July, 1988. Abstracts. Br J Clin Pharmacol (1988) 0.75
Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine. Ann Intern Med (1975) 1.57
Kinetics of CO2-HCO3 minus in normal adult males. J Nucl Med (1970) 1.49
Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis. N Engl J Med (1974) 1.47
Urinary D-glucaric acid assay by an improved enzymatic procedure. Clin Chim Acta (1974) 1.42
Aminopyrine demethylation measured by breath analysis in cirrhosis. Clin Pharmacol Ther (1976) 1.35
Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination. J Lab Clin Med (1977) 1.13
Rate of drug metabolism in man measured by 14CO2-breath analysis. Eur J Clin Pharmacol (1978) 1.08
The features of hepatic enzyme induction with glutethimide in man. Br J Clin Pharmacol (1978) 1.02
Assessment of the (14C) aminopyrine breath test in liver disease. Gut (1978) 0.89
Aminopyrine metabolism in the presence of hyperbilirubinemia due to cholestasis or hepatocellular disease. Combined use of laboratory tests to study disease-induced alterations in drug disposition. Clin Pharmacol Ther (1977) 0.88
Effect of subacute administration of methaqualone, phenobarbital and glutethimide on plasma levels of bishydroxycoumarin. Arch Int Pharmacodyn Ther (1972) 0.85
Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA (2000) 8.06
Review of company postmarketing surveillance studies. BMJ (1992) 6.21
Prospective audit of upper gastrointestinal endoscopy in two regions of England: safety, staffing, and sedation methods. Gut (1995) 4.70
Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. Br Med J (Clin Res Ed) (1985) 4.30
Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"? Br Med J (1977) 4.20
Uses of barium meal examination in dyspeptic patients under 50. Br Med J (1977) 3.82
Bioethics for clinicians: 1. Consent. CMAJ (1996) 3.60
Treatment of gastric ulcer with carbenoxolone: antagonistic effect of spironolactone. Gut (1968) 3.46
"Black blood" T2-weighted inversion-recovery MR imaging of the heart. Radiology (1996) 3.34
Towards estimation and confidence intervals. Br Med J (Clin Res Ed) (1986) 3.22
Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. BMJ (1992) 3.17
Sedation for upper gastrointestinal endoscopy: results of a nationwide survey. Gut (1991) 3.14
20 years of hospital admissions for peptic ulcer in England and Wales. Lancet (1981) 3.06
Changing patterns in epidemiology of Crohn's disease. Lancet (1974) 2.99
Epidemiology of Burkholderia cepacia infection in patients with cystic fibrosis: analysis by randomly amplified polymorphic DNA fingerprinting. J Clin Microbiol (1996) 2.95
Postmarketing surveillance of the safety of cimetidine: 12 month mortality report. Br Med J (Clin Res Ed) (1983) 2.90
Pattern of non-steroidal anti-inflammatory drug use in Australia 1990-1994. A report from the Drug Utilization Sub-Committee of the Pharmaceutical Benefits Advisory Committee. Med J Aust (1996) 2.78
Effect of different operation policies on mortality from bleeding peptic ulcer. Lancet (1979) 2.74
14C-urea breath analysis, a non-invasive test for Campylobacter pylori in the stomach. Lancet (1987) 2.68
Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet (1994) 2.62
Prevention of hypoxaemia during upper-gastrointestinal endoscopy by means of oxygen via nasal cannulae. Lancet (1987) 2.60
Aspirin, paracetamol, and haematemesis and melaena. Gut (1982) 2.55
Gallstone dissolution in man using chenodeoxycholic acid. Lancet (1972) 2.55
Epidemiological evidence for the association of aspirin and acute gastrointestinal bleeding. Gut (1970) 2.55
Childhood factors in ulcerative colitis and Crohn's disease. An international cooperative study. Scand J Gastroenterol (1987) 2.54
Double-blind trial of linoleate supplementation of the diet in multiple sclerosis. Br Med J (1973) 2.53
Non-prescription use of bronchodilator aerosols. Med J Aust (1992) 2.41
Cimetidine and gastric cancer: preliminary report from post-marketing surveillance study. Br Med J (Clin Res Ed) (1982) 2.40
Intravenous midazolam: a study of the degree of oxygen desaturation occurring during upper gastrointestinal endoscopy. Br J Clin Pharmacol (1987) 2.36
Depth of insertion at flexible sigmoidoscopy: implications for colorectal cancer screening and instrument design. Endoscopy (1999) 2.23
Attitudes of physicians and public to pharmaceutical industry 'gifts'. Intern Med J (2010) 2.20
Giving and receiving of gifts between pharmaceutical companies and medical specialists in Australia. Intern Med J (2006) 2.19
Intravenous contrast media: use and associated mortality. Med J Aust (1991) 2.18
Smoking and Crohn's disease. Br Med J (Clin Res Ed) (1984) 2.17
Changes to the Pharmaceutical Benefits Advisory Committee. Med J Aust (2001) 2.14
ABO blood group and secretor status in relation to clinical characteristics of peptic ulcers. Gut (1965) 2.11
Gastric and duodenal ulcer and their associated diseases. Lancet (1976) 2.10
Cimetidine and ranitidine: comparison of effects on hepatic drug metabolism. Br Med J (1980) 2.09
Post-marketing surveillance of the safety of cimetidine: twelve-month morbidity report. Q J Med (1985) 2.07
Smoking and ulcerative colitis. Br Med J (Clin Res Ed) (1984) 2.05
Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med (2000) 2.04
Cigarette smoking and inflammatory bowel disease. Gastroenterology (1987) 2.04
Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis (2001) 2.04
Aspirin and bleeding peptic ulcers in the elderly. BMJ (1988) 2.00
Use of cloned probes to detect Epstein-Barr viral DNA in tissues of patients with neoplastic and lymphoproliferative diseases. J Infect Dis (1983) 1.99
Chenodeoxycholic acid treatment of gallstones. A follow-up report and analysis of factors influencing response to therapy. N Engl J Med (1975) 1.97
Controlled trial of maintenance cimetidine treatment in healed duodenal ulcer: short and long-term effects. Gut (1979) 1.90
Comparison of surgical and medical management of bleeding peptic ulcers. Br Med J (Clin Res Ed) (1982) 1.90
Simple half-gram stain for showing presence of Campylobacter pyloridis in sections. J Clin Pathol (1987) 1.84
Epidemiology of cancer of the large intestine. Proc R Soc Med (1966) 1.83
A prospective, randomised study of endoscopy and radiology in acute upper-gastrointestinal-tract bleeding. Lancet (1977) 1.81
Postmarketing surveillance of the safety of cimetidine: mortality during second, third, and fourth years of follow up. Br Med J (Clin Res Ed) (1985) 1.78
Changes in drug metabolism with increasing age: 2. phenytoin clearance and protein binding. Br J Clin Pharmacol (1975) 1.76
Factors influencing human gallstone dissolution in monkey, dog, and human bile. Gut (1972) 1.73
Faecal stasis in proctocolitis. Gut (1962) 1.71
The late results of medical and surgical treatment for bleeding duodenal ulcer. Q J Med (1970) 1.70
What is happening to peptic ulcer? Br Med J (Clin Res Ed) (1982) 1.70
Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut (2000) 1.69
Audit of mortality in upper gastrointestinal bleeding. Postgrad Med J (1989) 1.68
Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning. Med J Aust (1989) 1.68
Helicobacter pylori eradication in patients with peptic ulcer disease: clinical consequences and financial implications. Q J Med (1994) 1.67
Prospective evaluation of the McMurray test. Am J Sports Med (1993) 1.64
Cimetidine and ranitidine in duodenal ulcer. Br Med J (1980) 1.63
The value of radiology in predicting gallstone type when selecting patients for medical treatment. Gut (1975) 1.58
Anti-Helicobacter pylori therapy: clearance, elimination, or eradication? Lancet (1991) 1.57
Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication. Aliment Pharmacol Ther (1991) 1.56
The demographic and social characteristics of patients with Crohn's disease in the Nottingham area. Scand J Gastroenterol (1976) 1.54
Long-term study of re-infection following successful eradication of Helicobacter pylori infection. Aliment Pharmacol Ther (2006) 1.54
Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers. J Clin Invest (1982) 1.54
Prospective audit of perforation rates following upper gastrointestinal endoscopy in two regions of England. Br J Surg (1995) 1.53
Bioethics for clinicians: 2. Disclosure. CMAJ (1996) 1.53
Coincident salmonella infections and ulcerative colitis: problems of recognition and management. Br Med J (1974) 1.51
Colonoscopy--is sedation necessary and is there any role for intravenous propofol? Endoscopy (2000) 1.51
Evaluation of a nurse-led telephone clinic in the follow-up of patients with malignant glioma. Clin Oncol (R Coll Radiol) (2000) 1.49
The benefits of reducing cholesterol levels: the need to distinguish primary from secondary prevention. 1. A meta-analysis of cholesterol-lowering trials. Med J Aust (1991) 1.47
Changes in drug metabolism with increasing age: 1. warfarin binding and plasma proteins. Br J Clin Pharmacol (1975) 1.46
Outcome of endoscopy and barium radiography for acute upper gastrointestinal bleeding: controlled trial in 1037 patients. Br Med J (Clin Res Ed) (1982) 1.46
Influence of diet on the "intestinal" component of serum alkaline phosphatase in people of different ABO blood groups and secretor status. Nature (1966) 1.44
Effect of different doses of chenodeoxycholic acid on bile-lipid composition and on frequency of side-effects in patients with gallstones. Lancet (1974) 1.44
Treatment of gastric ulcer with oestrogens. Gut (1968) 1.44
Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev (2002) 1.43
Upper gastrointestinal bleeding: the trials of trials. Gut (1985) 1.42
Patients as a direct source of information on adverse drug reactions. BMJ (1988) 1.42
Systematic review and meta-analysis of the use of fibrin sealant to prevent seroma formation after breast cancer surgery. Br J Surg (2006) 1.41
The present position concerning gallstone dissolution. Gut (1974) 1.41
Recent changes in the profile of prescription NSAID use in Australia. Med J Aust (2000) 1.41
Cimetidine maintenance: How long? Lancet (1978) 1.40
Skeletal applications of videofluoroscopy. J Manipulative Physiol Ther (1990) 1.40
Tiguvon spot-on and flea control in dogs and cats. Vet Rec (1997) 1.39
Protection of the bovine fetus from bovine viral diarrhoea virus by means of a new inactivated vaccine. Vet Rec (1995) 1.39
Somatostatin in treatment of haematemesis and melaena. Lancet (1985) 1.39
Consent and sterilization. Can Med Assoc J (1978) 1.38
Glucomannan and risk of oesophageal obstruction. Br Med J (Clin Res Ed) (1986) 1.38